Your browser doesn't support javascript.
loading
Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab.
Moreira, Raphael B; Hamieh, Lana; Gjini, Evisa; Lako, Ana; Krajewski, Katherine M; Yoon, Charles H; Ott, Patrick A.
Afiliación
  • Moreira RB; Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
  • Hamieh L; Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
  • Gjini E; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Lako A; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Krajewski KM; Department of Imaging, Dana Farber Cancer Institute, Brigham and Women's Hospital Harvard Medical School, Boston, MA, USA.
  • Yoon CH; Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Ott PA; Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA. Patrick_Ott@dfci.harvard.edu.
J Immunother Cancer ; 5(1): 61, 2017 07 18.
Article en En | MEDLINE | ID: mdl-28716097
BACKGROUND: Spontaneous regression of metastatic melanoma and delayed responses more than one year after treatment with ipilimumab are rarely seen. CASE PRESENTATION: Here, we present the case of a patient with in transit metastases from cutaneous melanoma on his right lower extremity who achieved complete regression of all metastatic lesions 13 months after the first of two consecutive palliative resections of dominant masses and more than two years after treatment with ipilimumab. CONCLUSION: The exact cause of our patient's sudden onset of tumor regression remains speculative. We hypothesize that the operative trauma followed by the postoperative infections augmented an innate immune response.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Ipilimumab / Antineoplásicos Inmunológicos / Melanoma Límite: Aged80 / Humans / Male Idioma: En Revista: J Immunother Cancer Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Ipilimumab / Antineoplásicos Inmunológicos / Melanoma Límite: Aged80 / Humans / Male Idioma: En Revista: J Immunother Cancer Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido